The DevelopAKUre programme is a major international clinical trial, run by the AKU Society and supported by a huge European network, including 13 hospitals, pharmaceutical companies and consultancies, universities, biotech companies and national AKU patient groups. The countries involved include: UK, France, Italy, The Netherlands, Poland, the US, Canada, Slovakia, Jordan, Germany, Sweden and others.
The DevelopAKUre clinical trial programme will be assessing the drug nitisinone as a potential treatment for the rare disease alkaptonuria (AKU).
If you are a patient interested in participating, or would like to find out more information about the programme, please do so by registering your interest and our Clinical Trials Coordinator, Hana Ayoob, will be in touch.
If you're unsure about participating, an appointment with your regular doctor may help you to decide.
In addition, the trial centre staff will be pleased to provide you with more information about the programme and answer any of your questions.
DevelopAKUre is a series of major international clinical trials, run by a consortium of 12 European partners. It aims to study a potential new drug, called nitisinone, and assess its potential effectiveness in treating the rare disease, alkaptonuria (AKU).
DevelopAKUre is co-funded by a grant from the European Commission. This website is run by a UK patient group, the AKU Society. Learn more about AKU on the AKU Society's What is AKU page.
In today’s blog Chief investigator Prof. Ranganath reinforces the need for SONIA 2 pat.. ...more